Sign In
Buy DCPH
$25.59
+0 (+0%)
At Close: Sep 09, 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, February 9, 2021
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones
07:00am, Monday, 11'th Jan 2021
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer,
Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
07:23am, Tuesday, 05'th Jan 2021
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan He
4 Biotechs That Could Be Potential Acquisition Targets in 2021
10:32am, Thursday, 17'th Dec 2020
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the completion of its target enrollment in the INTRIGUE Phase 3 clinical study evaluating the efficacy an
The Boston Globe Names Deciphera a Top Place to Work for 2020
07:00am, Monday, 23'rd Nov 2020
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer,
Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
07:01am, Wednesday, 11'th Nov 2020
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced data presentations from clinical studies of QINLOCK, the Company's switch-control tyrosine kinase inhibi
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q3 2020 Results - Earnings Call Transcript
05:38am, Sunday, 08'th Nov 2020
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q3 2020 Results - Earnings Call Transcript
2 reasons why I would buy DCC at the current share price
10:01am, Friday, 02'nd Oct 2020
The DCC share price is dropping but I think now is the time to be greedy with its stock, says Rachael FitzGerald-Finch.
2 reasons why I would buy DCC at the current share price
12:00am, Friday, 02'nd Oct 2020
2 reasons why I would buy DCC at the current share price
Covalon Technologies (OTCMKTS:CVALF) & DCC (OTCMKTS:DCCPF) Financial Comparison
02:46am, Friday, 25'th Sep 2020
DCC (OTCMKTS:DCCPF) and Covalon Technologies (OTCMKTS:CVALF) are both business services companies, but which is the better business? We will contrast the two businesses based on the strength of their
The Global Sexual Enhancement Supplements Market will grow by $ 407.16 mn during 2020-2024
Citi Launches Direct Custody and Clearing Services in Finland
12:00am, Tuesday, 25'th Aug 2020
Citi will begin offering Direct Custody & Clearing (DCC) services in Finland, starting in August. This new offering expands Citi’s proprietary DCC
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that the Journal of Clinical Oncology has published results from its Phase 1 study of QINLOCK, the Company’s switch-control tyrosine ki
INOVIO Reports Second Quarter 2020 Financial Results; Provides DNA Medicines Clinical Program Mid-Year Update
08:05pm, Monday, 10'th Aug 2020
PLYMOUTH MEETING, Pa., Aug. 10, 2020 /PRNewswire via COMTEX/ --
PLYMOUTH MEETING, Pa., Aug. 10, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology...
